Table 2. Groups that discontinued and continued the drug during polypectomy.
| Medication continued | Medication discontinued | P | ||||
|---|---|---|---|---|---|---|
| Median ± SD or n (%) | Median | Median ± SD or n (%) | Median | |||
| Age | 64.2 ± 9.0 | 62.5 | 64.5 ± 5.8 | 64.5 | 0.741m | |
| Sex | Female | 20 (33.3%) | 9 (26.5%) | 0.489χ² | ||
| Male | 40 (66.7%) | 25 (73.5%) | ||||
| Indication | Malignancy screening | 31 (51.7%) | 14 (41.2%) | 0.328χ² | ||
| Anemia | 29 (48.3%) | 20 (58.8%) | ||||
| Disease | Atrial fibrillation | 2 (3.3%) | 7 (20.6%) | 0.006χ² | ||
| Coronary bypass | 4 (6.7%) | 2 (5.9%) | 0.881χ² | |||
| CAD | 26 (43.3%) | 5 (14.7%) | 0.005χ² | |||
| Mitral valve replacement | 3 (5.0%) | 5 (14.7%) | 0.105χ² | |||
| Cardiac stents | 23 (38.3%) | 13 (38.2%) | 0.993χ² | |||
| Cardiac insufficiency | 2 (3.3%) | 2 (5.9%) | 0.618χ² | |||
| Antithrombotic | Aspirin (100 mg) | 33 (55.0%) | 9 (26.5%) | 0.008χ² | ||
| Warfarin | 4 (6.7%) | 12 (35.3%) | 0.000χ² | |||
| Clopidogrel | 13 (21.7%) | 11 (32.4%) | 0.254χ² | |||
| Clopidogrel + aspirin | 2 (3.3%) | 0 (0.0%) | 0.533χ² | |||
| Rivaroxaban | 8 (13.3%) | 2 (5.9%) | 0.260χ² | |||
| LMWH bridging | No | 60 (100.0%) | 8 (23.5%) | 0.000χ² | ||
| Yes | 0 (0.0%) | 26 (76.5%) | ||||
| Diabetes mellitus | No | 46 (76.7%) | 23 (67.6%) | 0.342χ² | ||
| Yes | 14 (23.3%) | 11 (32.4%) | ||||
| Hypertension | No | 32 (53.3%) | 13 (38.2%) | 0.159χ² | ||
| Yes | 28 (46.7%) | 21 (61.8%) | ||||
| Bleeding | No | 58 (96.7%) | 33 (97.1%) | 1.000χ² | ||
| Yes | 1 (1.7%) | 1 (2.9%) | ||||
| Platelets | 231.8 ± 64.1 | 225.0 | 249.2 ± 54.5 | 250.0 | 0.040m | |
| INR | 1.1 ± 0.2 | 1.0 | 1.2 ± 0.3 | 1.1 | 0.009m | |
mMann-Whitney U test; χ²chi-square test. SD = standard deviation; CAD = coronary artery disease; LMWH = low molecular weight heparin; INR = international normalized ratio.